The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics-Reference-Cited by-同舟云学术

The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics

Published:2023 Issue:5 Volume:20 Page:9511-9529
ISSN:1551-0018
Container-title:Mathematical Biosciences and Engineering
language:
Short-container-title:MBE

Author:

Jiang Tongmeng¹²,Jin Pan³⁴,Huang Guoxiu⁵,Li Shi-Cheng⁶

Affiliation:

1. Key Laboratory of Hainan Trauma and Disaster Rescue, The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou 571199, China

2. Engineering Research Center for Hainan Bio-Smart Materials and Bio-Medical Devices, Key Laboratory of Hainan Functional Materials and Molecular Imaging, Key Laboratory of Emergency and Trauma, Ministry of Education, College of Emergency and Trauma, Hainan Medical University, Haikou 571199, China

3. Health Science Center, Yangtze University, Jingzhou 434023, China

4. Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning 530021, China

5. Health Management Center, The People's Hospital of Guangxi Zhuang Autonomous Region; Guangxi Health Examination Center, Nanning 530021, China

6. Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region; Institute of Cardiovascular Sciences, Guangxi Academy of Medical Sciences, Nanning 530021, China

Abstract

<abstract> <p>As a guanylate binding protein (GBPs) member, GBP3 is immune-associated and may participate in oncogenesis and cancer therapy. Since little has been reported on GBP3 in this field, we provide pan-cancer bioinformatics to investigate the role of GBP3 in human cancers. The GBP3 expression, related clinical outcomes, immune infiltrates, potential mechanisms and mutations were conducted using tools including TIMER2.0, GEPIA2.0, SRING, DAVID and cBioPortal. Results showed an increased risk of high GBP3 in Brain Lower Grade Glioma (LGG) and Lung Squamous Cell Carcinoma (LUSC) and a decreased risk of GBP3 in Sarcoma (SARC) and Skin Cutaneous Melanoma (SKCM) (p ≤ 0.05). GBP3 was negatively correlated with CAFs in Esophageal Adenocarcinoma (ESCA) and positively correlated with CAFs in LGG, LUSC and TGCG (p ≤ 0.05). In addition, GBP3 was positively correlated with CD8+ T cells in Bladder Urothelial Carcinoma (BLCA), Cervical Squamous Cell Carcinoma (CESC), Kidney Renal Clear Cell Carcinoma (KIRC), SARC, SKCM, SKCM-Metastasis and Uveal Melanoma (UVM) (p ≤ 0.05). Potentially, GBP3 may participate in the homeostasis between immune and adaptive immunity in cancers. Moreover, the most frequent mutation sites of GBP3 in cancers are R151Q/<sup>*</sup> and K380N. This study would provide new insight into cancer prognosis and therapy.</p> </abstract>

Publisher

American Institute of Mathematical Sciences (AIMS)

Subject

Applied Mathematics,Computational Mathematics,General Agricultural and Biological Sciences,Modeling and Simulation,General Medicine

Reference53 articles.

1. J. V. Corte-Real, H. M. Baldauf, J. Abrantes, P. J. Esteves, Evolution of the guanylate binding protein (GBP) genes: Emergence of GBP7 genes in primates and further acquisition of a unique GBP3 gene in simians, Mol. Immunol., 132 (2021), 79–81. https://doi.org/10.1016/j.molimm.2021.01.025

2. S. Huang, Q. Meng, A. Maminska, J. D. MacMicking, Cell-autonomous immunity by IFN-induced GBPs in animals and plants, Curr. Opin. Immunol., 60 (2019), 71–80. https://doi.org/10.1016/j.coi.2019.04.017

3. K. Tretina, E. S. Park, A. Maminska, J. D. MacMicking, Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease, J. Exp. Med., 216 (2019), 482–500. https://doi.org/10.1084/jem.20182031

4. K. Lipnik, E. Naschberger, N. Gonin-Laurent, P. Kodajova, H. Petznek, S. Rungaldier, et al., Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice, Mol. Med., 16 (2010), 177–187. https://doi.org/10.2119/molmed.2009.00172

5. P. Godoy, C. Cadenas, B. Hellwig, R. Marchan, J. Stewart, R. Reif, et al., Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response, Breast Cancer, 21 (2014), 491–499. https://doi.org/10.1007/s12282-012-0404-8